Cargando…

Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis

BACKGROUND: We explored whether clinically relevant baseline characteristics of patients with type 2 diabetes can modify the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) or sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on the risk of major adverse cardiovascular events (MACE)...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Andrea, Elvira, Kesselheim, Aaron S., Franklin, Jessica M., Jung, Emily H., Hey, Spencer Phillips, Patorno, Elisabetta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525990/ https://www.ncbi.nlm.nih.gov/pubmed/32993654 http://dx.doi.org/10.1186/s12933-020-01133-1

Ejemplares similares

Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
por: D’Andrea, Elvira, et al.
Publicado: (2019)

Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States
por: Bykov, Katsiaryna, et al.
Publicado: (2020)

A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes
por: Gyawali, Bishal, et al.
Publicado: (2018)

Public Approval of Exception From Informed Consent in Emergency Clinical Trials: A Systematic Review of Community Consultation Surveys
por: Feldman, William B., et al.
Publicado: (2019)

Association of Prior Intracerebral Hemorrhage With Major Adverse Cardiovascular Events
por: Gaist, David, et al.
Publicado: (2022)

A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer
por: Gyawali, Bishal, et al.
Publicado: (2021)

Cardiac rehabilitation performance predicts 1‐year major adverse cardiovascular events
por: Naami, Robert, et al.
Publicado: (2022)

An Uninformative Truth: The Logic of Amarin’s Off-Label Promotion
por: Hey, Spencer Phillips, et al.
Publicado: (2016)

Four‐year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation
por: Miao, Benjamin, et al.
Publicado: (2020)

Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA(1c) Levels
por: D’Andrea, Elvira, et al.
Publicado: (2023)

Heterogeneous plaque–lumen geometry is associated with major adverse cardiovascular events
por: Gu, Sophie Z, et al.
Publicado: (2023)

Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke
por: Tu, Wen-Jun, et al.
Publicado: (2020)

Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus
por: Fu, Liyao, et al.
Publicado: (2021)

Cardio‐ankle vascular index as a predictor of major adverse cardiovascular events in metabolic syndrome patients
por: Limpijankit, Thosaphol, et al.
Publicado: (2021)

Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real‐world evidence study
por: Chen, Guanmin, et al.
Publicado: (2021)

Waist circumference is associated with major adverse cardiovascular events in male but not female patients with type-2 diabetes mellitus
por: Xing, Zhenhua, et al.
Publicado: (2020)

High‐density lipoprotein cholesterol levels are associated with major adverse cardiovascular events in male but not female patients with hypertension
por: Wang, Xiaopu, et al.
Publicado: (2021)

Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes
por: Zhuo, Min, et al.
Publicado: (2022)

Combination of coronary CT angiography, FFR(CT), and risk factors in the prediction of major adverse cardiovascular events in patients suspected CAD
por: Wada, Shinichi, et al.
Publicado: (2023)

Association of Lipoprotein(a) Levels With Incidence of Major Adverse Limb Events
por: Guédon, Alexis F., et al.
Publicado: (2022)

Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients
por: Zhai, Mike Z., et al.
Publicado: (2022)

Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes: a 7-year follow-up study
por: Blanc-Bisson, C., et al.
Publicado: (2018)

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
por: Kaze, Arnaud D., et al.
Publicado: (2022)

Major adverse cardiac events and drug-coated balloon size in coronary interventions
por: Naguib, David, et al.
Publicado: (2018)

Impact of diabetes duration and degree of carotid artery stenosis on major adverse cardiovascular events: a single-center, retrospective, observational cohort study
por: Noh, Minsu, et al.
Publicado: (2017)

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
por: Patorno, Elisabetta, et al.
Publicado: (2018)

Major Cardiovascular Events After Spontaneous Intracerebral Hemorrhage by Hematoma Location
por: Boe, Nils Jensen, et al.
Publicado: (2023)

Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis
por: Hoogwerf, Byron J., et al.
Publicado: (2016)

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data
por: Young, James B., et al.
Publicado: (2018)

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
por: Gyawali, Bishal, et al.
Publicado: (2020)

Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
por: Fei, Yue, et al.
Publicado: (2019)

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Gender differences in adverse event reports associated with antidiabetic drugs
por: Joung, Kyung-In, et al.
Publicado: (2020)

Order Substitutions and Education for Balanced Crystalloid Solution Use in an Integrated Health Care System and Association With Major Adverse Kidney Events
por: Bledsoe, Joseph, et al.
Publicado: (2022)

Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors: A Systematic Review and Meta-analysis
por: Mincu, Raluca I., et al.
Publicado: (2019)

Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome
por: Wang, Le, et al.
Publicado: (2020)

Derivation of Patient-Defined Adverse Cardiovascular and Noncardiovascular Events Through a Modified Delphi Process
por: Sun, Louise Y., et al.
Publicado: (2021)

Sortilin levels correlate with major cardiovascular events of diabetic patients with peripheral artery disease following revascularization: a prospective study
por: Biscetti, Federico, et al.
Publicado: (2020)

Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor
por: Lee, Hsin-Fu, et al.
Publicado: (2020)

Comparison of Mortality and Major Cardiovascular Events Among Adults With Type 2 Diabetes Using Human vs Analogue Insulins
por: Neugebauer, Romain, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jj99f68ua54shginqimo6ms2ll